Nuclear medicine

MILabs VECT or system is an extremely user-friendly; therefore fully integrate multimodal imaging technology use for the development of new diagnostic solutions and therapies. With its latest adaptive preclinical platform; therefore MILabs has succeed at commercializing a scalable imaging platform; able to accommodate PET, SPECT, Optical, and CT imaging in a single system.

New diagnostic solutions

Awarded the Commercial Innovation of the Year 2018 at the Molecular Imaging Congress; this platform is globally recognize for being able to deliver the highest quality molecular; functional and anatomical images. Because The MILabs VECTor (OI/CT) system has been acquired by the Department of Radiology at Columbia University Irving Medical Center (CUIMC); to upgrade its molecular imaging capabilities.

They believe that the unique features of this new OI/CT system; including CT imaging from mice to rabbits, will enable novel translational research applications. In addition; therefore the exclusive synergy of optical and X-ray CT imaging allows for quantitative tomographic optical imaging of deep tissues in many mouse models of human diseases.”

Translational research applications

CUIMC provides global leadership in translational research, including near-infrared optical imaging. Because MILabs’ VECTor OI/CT system for hybrid optical/CT preclinical imaging system was chosen to support the Department of Radiology’s PET Center and the Irving Institute for Clinical and Translational Research at Columbia University.

Molecular imaging fundamentally changes the way we look at cancer. Imaging paradigms are now shifting away from classical morphological measures towards the assessment of functional, metabolic, cellular, and molecular information in vivo. Because Interdisciplinary driven developments of imaging methodology and probe molecules utilizing animal models of human cancers have enhanced our ability to non-invasively characterize neoplastic tissue and follow anti-cancer treatments.

Preclinical molecular imaging offers a whole palette of excellent methodology to choose from. They focus on positron emission tomography (PET) and magnetic resonance imaging (MRI) techniques; since they provide excellent and complementary molecular imaging capabilities and bear high potential for clinical translation. Because Prerequisites and consequences of using animal models as surrogates of human cancers in preclinical molecular imaging are outlined.

Magnetic resonance imaging

We present physical principles, values and limitations of PET and MRI as molecular imaging modalities and comment on their high potential to non-invasively assess information on hypoxia, angiogenesis, apoptosis, gene expression, metabolism, and cell trafficking in preclinical cancer research. Potential applications of PET molecular imaging capabilities open up new perspectives in the assessment of many different biological and functional processes; and thus the prospect of new tools for the detection and diagnosis of different diseases.
The Cell & Molecular Imaging (CMI) Shared Resource provides investigators with a fully supported suite of state-of-the-art imaging capabilities. These capabilities include imaging at the cellular, tissue, intravital and in vivo whole animal levels. The CMI Shared Resource consists of two synergistic and coordinated units the Confocal & Multiphoton Microscopy Unit and the Small Animal Imaging Unit.